FIBROGEN INC - COMMON

FibroGen Announces Non-Dilutive Term Loan Financing for up to $150 Million with Morgan Stanley Tactical Value

01 5 2023 07:00:00 提供 Nasdaq GlobeNewswire

FibroGen to Report First Quarter 2023 Financial Results

24 4 2023 07:00:00 提供 Nasdaq GlobeNewswire

FibroGen Announces Completion of Patient Enrollment in ZEPHYRUS-2, a Phase 3 Clinical Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis

03 4 2023 07:00:00 提供 Nasdaq GlobeNewswire

FibroGen Reports Fourth Quarter and Full Year 2022 Financial Results

27 2 2023 16:01:00 提供 Nasdaq GlobeNewswire

FibroGen to Present at Cowen’s 43rd Annual Health Care Conference

27 2 2023 07:00:00 提供 Nasdaq GlobeNewswire

FibroGen to Report Fourth Quarter and Full Year 2022 Financial Results

17 2 2023 07:00:00 提供 Nasdaq GlobeNewswire

FibroGen to Present at SVB Securities Global Biopharma Conference

02 2 2023 07:00:00 提供 Nasdaq GlobeNewswire

FibroGen to Participate at Bank of America 2022 Biotech SMID Cap Virtual Conference

28 11 2022 07:00:00 提供 Nasdaq GlobeNewswire

FibroGen Reports Third Quarter 2022 Financial Results

07 11 2022 16:01:00 提供 Nasdaq GlobeNewswire

FibroGen Announces $50 Million Royalty Monetization Financing with NovaQuest Capital Management

07 11 2022 16:00:00 提供 Nasdaq GlobeNewswire

FibroGen to Participate at Stifel 2022 Healthcare Conference

01 11 2022 07:00:01 提供 Nasdaq GlobeNewswire

FibroGen to Report Third Quarter 2022 Financial Results

24 10 2022 07:00:00 提供 Nasdaq GlobeNewswire

FibroGen Announces Completion of Patient Enrollment in MATTERHORN, a Phase 3 Clinical Study of Roxadustat for the Treatment of Anemia in Patients with Lower Risk Transfusion-Dependent Myelodysplastic Syndromes (MDS)

26 8 2022 07:00:00 提供 Nasdaq GlobeNewswire

FibroGen Reports Second Quarter 2022 Financial Results

08 8 2022 16:01:00 提供 Nasdaq GlobeNewswire

FibroGen to Report Second Quarter 2022 Financial Results

25 7 2022 07:00:33 提供 Nasdaq GlobeNewswire

FibroGen to Participate at William Blair Biotech Focus Conference 2022

01 7 2022 07:00:00 提供 Nasdaq GlobeNewswire

FibroGen Announces Completion of Patient Enrollment in LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Duchenne Muscular Dystrophy

08 6 2022 07:00:01 提供 Nasdaq GlobeNewswire

FibroGen to Present at Jefferies Healthcare Conference

26 5 2022 07:00:00 提供 Nasdaq GlobeNewswire

FibroGen Reports First Quarter 2022 Financial Results

09 5 2022 16:01:00 提供 Nasdaq GlobeNewswire

FibroGen to Report First Quarter 2022 Financial Results

25 4 2022 07:00:00 提供 Nasdaq GlobeNewswire